Please login to the form below

Not currently logged in
Email:
Password:

India revokes Pfizer's patent on Sutent

Loses patent protection for kidney cancer drug after Cipla and Natco challenge

Pfizer has become the latest Western drugmaker to fall foul of India's increasingly contentious intellectual property (IP) environment, losing patent protection for its kidney cancer drug Sutent.

The country's Patent Office revoked the basic patent for Sutent (sunitinib malate) on the grounds that it did not include an inventive step, backing the position taken up by Indian drugmakers Cipla and Natco Pharma in a legal challenge to Pfizer's IP.

Cipla had argued that the inventiveness of Pfizer's patent was compromised by "structural obviousness", in other words the compound's structure could have been deduced from similar drugs already covered by earlier patents.

Pfizer said immediately it would lodge an appeal against the Patent Office's decision, which is the third defeat for a major pharma company in India in as many weeks, all involving widely-used cancer drugs.

The company sells its Sutent product for 1.96 lakh (about $3,800) for a 45-day course, and Cipla says it will make its Sunitib version available at a 10 per cent discount, according to a LiveMint report.

Last month, Bayer failed in a bid to overturn a compulsory license which removed patent protection for its Nexavar (sorafenib) cancer drug, allowing a cut-price competitor from Natco to enter the market. 

Just a few days before the Nexavar verdict Roche lost a four-year legal dispute with Cipla over patent rights to Tarceva (erlotinib), while Novartis is still in the throes of a long-running legal dispute as it tries to defend blockbuster cancer drug Glivec (imatinib) and is expecting a verdict before the end of this year.

Pfizer had already protected Sutent from a compulsory license challenge in 2008, a year after the company was awarded its patent and launched the product, and in an interview with the Business Standard said the Patent Office's latest action "raised concerns over India's commitment to protect intellectual property".

5th October 2012

From: PME

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...
World Heart Day 2020: It's time to make our clinical trials more inclusive
September 29th is World Heart Day, a day dedicated to raising awareness about cardiovascular diseases and how everyone can take steps to prevent them. It’s common knowledge that smoking and...
Patient engagement
Taking a holistic approach to patient care
The importance of recognising each patient as an individual...

Infographics